About FDA
Cumulative number of Warning Letters issued for the FY against Tobacco Retailers (excluding internet based)
Dictionary: The Family Smoking Prevention and Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act and provided the FDA with several enforcement tools to utilize when regulated industry fails to comply with the law. These tools include: warning letter, civil money penalty, no-tobacco-sale order, seizure, injunction, and criminal prosecution.
Warning Letters are generally issued to tobacco product retailers the first time an inspection reveals that they are not in compliance with tobacco product requirements. The Warning Letters are available in a searchable database on the agency’s website at: http://www.accessdata.fda.gov/scripts/oce/inspections/oce_insp_searching.cfm. This database is updated weekly.
Information as of November 30, 2012
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 0 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 24 |
| Jan 2011 | N/A | 42 |
| Feb 2011 | N/A | 66 |
| Mar 2011 | N/A | 114 |
| Apr 2011 | N/A | 229 |
| May 2011 | N/A | 358 |
| Jun 2011 | N/A | 443 |
| Jul 2011 | N/A | 544 |
| Aug 2011 | N/A | 700 |
| Sep 2011 | N/A | 1,019 |
Number of Warning Letters issued in the month against Tobacco Retailers (excluding internet based)
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 0 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 24 |
| Jan 2011 | N/A | 18 |
| Feb 2011 | N/A | 24 |
| Mar 2011 | N/A | 48 |
| Apr 2011 | N/A | 115 |
| May 2011 | N/A | 129 |
| Jun 2011 | N/A | 85 |
| Jul 2011 | N/A | 101 |
| Aug 2011 | N/A | 156 |
| Sep 2011 | N/A | 319 |
FY 2011 Total: 1,019
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
